These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16450853)

  • 21. Tree-based models for survival data with competing risks.
    Kretowska M
    Comput Methods Programs Biomed; 2018 Jun; 159():185-198. PubMed ID: 29650312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical recommendations for reporting Fine-Gray model analyses for competing risk data.
    Austin PC; Fine JP
    Stat Med; 2017 Nov; 36(27):4391-4400. PubMed ID: 28913837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regression modeling of competing risk using R: an in depth guide for clinicians.
    Scrucca L; Santucci A; Aversa F
    Bone Marrow Transplant; 2010 Sep; 45(9):1388-95. PubMed ID: 20062101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the effect of a partly unobserved, exogenous, binary time-dependent covariate on survival probabilities using generalised pseudo-values.
    Pötschger U; Heinzl H; Valsecchi MG; Mittlböck M
    BMC Med Res Methodol; 2018 Jan; 18(1):14. PubMed ID: 29351735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced-rank proportional hazards regression and simulation-based prediction for multi-state models.
    Fiocco M; Putter H; van Houwelingen HC
    Stat Med; 2008 Sep; 27(21):4340-58. PubMed ID: 18425994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic pseudo-observations: a robust approach to dynamic prediction in competing risks.
    Nicolaie MA; van Houwelingen JC; de Witte TM; Putter H
    Biometrics; 2013 Dec; 69(4):1043-52. PubMed ID: 23865523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The graft-versus-leukaemia effect after allogeneic bone-marrow transplantation: assessment through competing risks approaches.
    Katsahian S; Porcher R; Mary JY; Chevret S
    Stat Med; 2004 Dec; 23(24):3851-63. PubMed ID: 15580602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Competing risks regression for clustered data.
    Zhou B; Fine J; Latouche A; Labopin M
    Biostatistics; 2012 Jul; 13(3):371-83. PubMed ID: 22045910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in statistical reports and analysis on one and the same medical question. The Leukemia Working Partly.
    Hermans J; Boström L; Gratwohl A; Labopin M; Nilson B; Suciu S; de Vol E
    Bone Marrow Transplant; 1991; 7 Suppl 2():136. PubMed ID: 1878680
    [No Abstract]   [Full Text] [Related]  

  • 30. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing predictions among competing risks models with time-dependent covariates.
    Cortese G; Gerds TA; Andersen PK
    Stat Med; 2013 Aug; 32(18):3089-101. PubMed ID: 23494745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of censoring in competing risks analysis of the subdistribution hazard.
    Donoghoe MW; Gebski V
    BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic prediction by landmarking in competing risks.
    Nicolaie MA; van Houwelingen JC; de Witte TM; Putter H
    Stat Med; 2013 May; 32(12):2031-47. PubMed ID: 23086627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes.
    Poguntke I; Schumacher M; Beyersmann J; Wolkewitz M
    BMC Med Res Methodol; 2018 Jul; 18(1):79. PubMed ID: 30012114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Semi-parametric inferences for association with semi-competing risks data.
    Ghosh D
    Stat Med; 2006 Jun; 25(12):2059-70. PubMed ID: 16196081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic bone marrow transplantation for leukemia in Europe: regional differences. Report from the Leukemia Working party of the European Group for Bone Marrow Transplantation.
    Gratwohl A; Hermans J; Barrett AJ; Ernst P; Frassoni F; Gahrton G; Granena A; Kolb HJ; Prentice HG; Vernant JP
    Bone Marrow Transplant; 1990 Mar; 5(3):159-65. PubMed ID: 2331536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
    Geskus RB
    Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On graphical tests for proportionality of hazards in two samples.
    Sahoo S; Sengupta D
    Stat Med; 2016 Mar; 35(6):942-56. PubMed ID: 26522814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.
    Latouche A; Allignol A; Beyersmann J; Labopin M; Fine JP
    J Clin Epidemiol; 2013 Jun; 66(6):648-53. PubMed ID: 23415868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Semiparametric accelerated failure time cure rate mixture models with competing risks.
    Choi S; Zhu L; Huang X
    Stat Med; 2018 Jan; 37(1):48-59. PubMed ID: 28983935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.